1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow JAK2 Mutation: new trials by email Literature Review of JAK2 Mutation trials Research Report on JAK2 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-11-03 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
Polycythemia Vera (2) · Myeloproliferative Disorders (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1) · Venous Thromboembolism (1)
Bone Marrow Diseases (2) · Bone Marrow Neoplasms (2) · Hematologic Diseases (2) · Hematologic Neoplasms (2) · Hemic and Lymphatic Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Hemorrhagic Disorders (1) · Myeloproliferative Disorders (1) · Thrombocytosis (1) · Thromboembolism (1)
Aspirin (1) · Tablets (1) · apixaban (1)
Memorial Sloan Kettering Cancer Center (1) · Ottawa Hospital Research Institute (1)
Canada (1) · United States (1)
Aurelien Delluc, MD, PhD (1) · Miriam Kimpton, MD (1) · Raajit Rampal, MD, PhD (1)